Market Research Logo

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Prostate Cancer: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Prostate Cancer (2016-2026)
3.5.1 Diagnosed Incident Cases of Prostate Cancer
3.5.2 Age-Specific Incident Cases of Prostate Cancer
3.5.3 Incident Cases by Stage at Diagnosis
3.5.4 Incident Cases by Risk of Biochemical Recurrence
3.5.5 10-Year Diagnosed Prevalent Cases of Prostate Cancer
3.5.6 10-Year Prevalent CRPC Cases
3.5.7 10-Year Prevalent Metastatic Prostate Cancer Cases
3.5.8 10-Year Prevalent mCRPC Cases with HRD Mutations
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Prostate Cancer
Table 2: AJCC Staging of Prostate Cancer
Table 3: Risk Category Definitions
Table 4: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026
Table 5: 7MM, 10-Year Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026
Table 6: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016 and 2026
Figure 2: 7MM, Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016 and 2026
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Men, Ages ≥35 Years, 2006-2026
Figure 4: Sources Used and Not Used for Calculations of Incident Cases
Figure 5: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases
Figure 6: Sources Used and Not Used for Calculations of Diagnosed Incident Cases by Stage at Diagnosis and Metastases
Figure 7: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases of CRPC
Figure 8: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases with HRD Mutations
Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016
Figure 10: 7MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Men, Ages ≥35 Years, 2016
Figure 11: 7MM, Diagnosed Incident Cases of Prostate Cancer by Risk of Biochemical Recurrence, Men, Ages ≥35 Years, 2016
Figure 12: 7MM, 10-Year Prevalent Cases of CRPC, Men, Ages ≥35 Years, 2016
Figure 13: 7MM, 10-Year Prevalent Cases of Prostate Cancer by Metastases, Men, Ages ≥35 Years, 2016
Figure 14: 7MM, 10-Year Prevalent Cases of Prostate Cancer with HRD Mutations, Men, Ages ≥35 Years, 2016

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

Summary

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012 (IARC, 2017). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (ACS, 2017). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65, and patients often live long enough that they die of other causes (ACS, 2017).

In 2016, there were almost 0.5 million diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with around 150,000, or nearly 33% of cases in the 7MM, followed by Japan (about 100,000, or about 22.2% of cases). Spain had the lowest number of cases with nearly 26,000, or around 5.5% of cases in the 7MM. The number of cases in the 7MM is expected to grow to almost 550,000 by 2026, for an Annual Growth Rate (AGR) of 1.67%.

The US will still have the highest number of cases, with almost 186,000, at an AGR of over 2%, again followed by Japan (116,539 cases, AGR 1.16%). Spain will see the greatest growth (AGR around 2.5%), but will still have fewer cases than all other markets (around 32,000). Germany is expected to see the smallest increase in cases, with an AGR of nearly 1%. None of the countries are expected to see a decrease in cases.

In 2016, there were around 4.4 million prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the largest share of prevalent cases with around 1.8 million or just over 42% of cases in the 7MM. Japan had the next highest number of cases with nearly 0.7 million, followed by Germany with around 540,000. Spain had the lowest number of prevalent cases, with nearly 230,000, making up only for about 5% of cases in the 7MM.

The number of 10-year prevalent cases in the 7MM is expected to increase to about 4.6 million by 2026, for an AGR of about 0.4% per year. Japan is expected to see the greatest increase in prevalent cases: our epidemiologists predict around 1 million cases in 2026, for an AGR of about 4.8%. The UK, Spain, and Italy are also expected to see an increase in the number of cases. The US will still have the greatest number of cases in 2026 (around 1.5 million), but it is expected to see the greatest decrease in cases (AGR of negative 1.47%). France and Germany are also expected to see decreases in the number of 10-year diagnosed prevalent cases.

The report EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.

Scope

  • The Prostate Cancer EpiCast Report provides an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
  • The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Prostate Cancer EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
  • Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;